Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Rogado, J. [1 ]
Pacheco-Barcia, V. [1 ]
Fenor De la Maza, M. D. [1 ]
Serra, J. M. [2 ]
Toquero, P. [1 ]
Vera, B. [1 ]
Obispo, B. [1 ]
Mondejar, R. [1 ]
Ballesteros, A. [1 ]
Donnay, O. [1 ]
Colomer, R. [1 ]
Sanchez-Torres, J. M. [1 ]
机构：
[1] Hosp Univ La Princesa, Oncol Med, Madrid, Spain
[2] Hosp Univ La Princesa, Farm Dept, Madrid, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
anti PD-1; Nivolumab; Non-small-cell lung cancer;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-057
引用
收藏
页码：S1915 / S1916
页数：2
相关论文
共 50 条
  • [1] Nivolumab Experience in Patients with Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC) in Toledo, Spain
    Martinez Moreno, E.
    Irigoyen Medina, A.
    Martinez Barroso, K.
    Borregon Rivilla, M.
    Alvarez Cabellos, R.
    Cardenas, J. D.
    Andrade Santiago, J.
    Burgueno Lorenzo, I.
    Trujillo Alba, B.
    Chacon Lopez-Muniz, J. I.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2430 - S2430
  • [2] A cost utility analysis of erlotinib in patients with previously treated advanced non-small-cell lung cancer (NSCLC)
    Bradbury, P. A.
    Jang, R.
    Isogai, P.
    Mittmann, N.
    Evans, W.
    Shepherd, F. A.
    Leighl, N. B.
    Ng, R.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A72 - A72
  • [3] Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced non-small-cell lung cancer
    Lv, Weize
    Pei, Xiaofeng
    Zhao, Wenhua
    Cong, Yunyan
    Wei, Yajun
    Li, Ting
    Zhang, Hongyu
    Lin, Zhong
    Saito, Yuichi
    Kim, Jae Jun
    Liang, Zibin
    Zhong, Beilong
    Wang, Zhihui
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (02) : 201 - 212
  • [4] Are Inflammatory Markers Predictive of Nivolumab Efficacy in Advanced Non-Small-Cell Lung Cancer (NSCLC)?
    Rogado, J.
    Fenor De La Maza, M. D.
    Pacheco-Barcia, V.
    Serra, J. M.
    Toquero, P.
    Vera, B.
    Ballesteros, A.
    Mondejar, R.
    Donnay, O.
    Obispo, B.
    Colomer, R.
    Sanchez-Torres, J. M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2107 - S2108
  • [5] Second or Third Line Nivolumab Versus First Line Nivolumab in Patients with Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC)
    Martinez Moreno, E.
    Irigoyen Medina, A.
    Alvarez Cabellos, R.
    Martinez, K. A.
    Santiago, J.
    Rivilla, M.
    Cardenas, J. D.
    Esteban, C.
    Trujillo, B.
    Rosero, A.
    Fernandez, L.
    Ramos, I.
    Ramos, A.
    Chacon, J. I.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S536 - S537
  • [6] Long-term outcomes with nivolumab in patients with previously treated advanced Non-Small Cell Lung Cancer (NSCLC)
    Thomas, M.
    Kohlhaeufl, M.
    Reck, M.
    Engel-Riedel, W.
    Kortsik, C.
    Bullinger, L.
    Schneider, C. -P.
    Felip, E.
    Brahmer, J.
    Vokes, E.
    Gettinger, S.
    Geese, W.
    Yoon, D.
    Healey, D.
    Li, A.
    Eberhardt, W. E. E.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 137 - 137
  • [7] Gefitinib plus interleukin-2 in previously treated patients with advanced non-small-cell lung cancer (NSCLC)
    Longarini, Raffaella
    Buti, Sebastiano
    Bosio, Giancarlo
    Brighenti, Matteo
    Porzio, Rosa
    Negri, Federica
    Passalacqua, Rodolfo
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : 30 - 30
  • [8] Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England
    Ben Rothwell
    Christopher Kiff
    Caroline Ling
    Thor-Henrik Brodtkorb
    [J]. PharmacoEconomics - Open, 2021, 5 : 251 - 260
  • [9] Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England
    Rothwell, Ben
    Kiff, Christopher
    Ling, Caroline
    Brodtkorb, Thor-Henrik
    [J]. PHARMACOECONOMICS-OPEN, 2021, 5 (02) : 251 - 260
  • [10] Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis
    Antonia, Scott J.
    Borghaei, Hossein
    Ramalingam, Suresh S.
    Horn, Leora
    De Castro Carpeno, Javier
    Pluzanski, Adam
    Burgio, Marco A.
    Garassino, Marina
    Chow, Laura Q. M.
    Gettinger, Scott
    Crino, Lucio
    Planchard, David
    Butts, Charles
    Drilon, Alexander
    Wojcik-Tomaszewska, Joanna
    Otterson, Gregory A.
    Agrawal, Shruti
    Li, Ang
    Penrod, John R.
    Brahmer, Julie
    [J]. LANCET ONCOLOGY, 2019, 20 (10): : 1395 - 1408
12345